Cargando…
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial
IMPORTANCE: Cerebral small vessel disease (cSVD) is a common cause of stroke (lacunar stroke), is the most common cause of vascular cognitive impairment, and impairs mobility and mood but has no specific treatment. OBJECTIVE: To test the feasibility, drug tolerability, safety, and effects of 1-year...
Autores principales: | Wardlaw, Joanna M., Woodhouse, Lisa J., Mhlanga, Iris I., Oatey, Katherine, Heye, Anna K., Bamford, John, Cvoro, Vera, Doubal, Fergus N., England, Timothy, Hassan, Ahamad, Montgomery, Alan, O’Brien, John T., Roffe, Christine, Sprigg, Nikola, Werring, David J., Bath, Philip M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209826/ https://www.ncbi.nlm.nih.gov/pubmed/37222252 http://dx.doi.org/10.1001/jamaneurol.2023.1526 |
Ejemplares similares
-
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
por: Bath, Philip M, et al.
Publicado: (2022) -
Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial
por: Appleton, Jason P., et al.
Publicado: (2019) -
Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial
por: Blair, Gordon W., et al.
Publicado: (2021) -
Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial
por: Blair, Gordon W., et al.
Publicado: (2019) -
Protocol: The Lacunar Intervention Trial 2 (LACI-2). A trial of two
repurposed licenced drugs to prevent progression of cerebral small vessel
disease
por: Wardlaw, Joanna, et al.
Publicado: (2020)